Compare Dollar General Corp. (DG) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar General Corp. vs Revvity Inc — how do they compare? Dollar General Corp. trades at $124.79 (market cap $27.42B), while Revvity Inc trades at $154.16 (market cap $16.98B). The key difference: Dollar General Corp. is the larger of the two by market cap, and Dollar General Corp. pays the higher dividend (1.9%). Which is the better fit depends on your goals — on Pluang, investors hold Dollar General Corp. for 59 Days and Revvity Inc for 12 Days on average.
| DG | RVTY | |
|---|---|---|
Market Cap | $27.42B | $16.98B |
Volume | 2,291,517 | 1,456,900 |
Sector | Consumer Staples | Health |
52-Week High | $156.26 | $157.36 |
52-Week Low | $95.94 | $82.26 |
Typical Hold Time | 59 Days | 12 Days |
Enterprise Value | $41.60B | $19.30B |
Dividend Yield | 1.9% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar General (DG) trades at $122.16, down 0.89% on the day, with a neutral technical signal. The stock shows strong fundamentals with a P/E of 16.14 and P/S of 0.63, indicating potential undervaluation. Recent earnings have consistently beaten estimates, with Q2 2026 EPS of $2.48 surpassing the $2.01 expectation. Positive news includes tariff refunds boosting margins and expansion of same-day delivery via Instacart, supporting growth initiatives.
The outlook is cautiously optimistic, with a consensus price target of $137.27 offering ~12% upside. Key opportunities include margin improvement from operational initiatives, while risks involve competitive pressures and potential consumer spending softness. Analyst sentiment is predominantly buy-rated (55.77%), though recent insider selling and mixed technical indicators warrant monitoring.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
